- Home
- IOVA vs KRP Comparison
IOVA vs KRP Comparison
Compare IOVA & KRP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- KRP
- Stock Information
- Founded
- IOVA 2007
- KRP 2013
- Country
- IOVA United States
- KRP United States
- Employees
- IOVA N/A
- KRP N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- KRP Oil & Gas Production
- Sector
- IOVA Health Care
- KRP Energy
- Exchange
- IOVA Nasdaq
- KRP Nasdaq
- Market Cap
- IOVA 975.1M
- KRP 1.1B
- IPO Year
- IOVA N/A
- KRP 2017
- Fundamental
- Price
- IOVA $2.30
- KRP $13.21
- Analyst Decision
- IOVA Buy
- KRP Hold
- Analyst Count
- IOVA 11
- KRP 5
- Target Price
- IOVA $11.90
- KRP $17.20
- AVG Volume (30 Days)
- IOVA 10.8M
- KRP 441.7K
- Earning Date
- IOVA 11-06-2025
- KRP 11-06-2025
- Dividend Yield
- IOVA N/A
- KRP 13.04%
- EPS Growth
- IOVA N/A
- KRP N/A
- EPS
- IOVA N/A
- KRP N/A
- Revenue
- IOVA $241,525,000.00
- KRP $312,566,668.00
- Revenue This Year
- IOVA $67.40
- KRP $9.34
- Revenue Next Year
- IOVA $56.32
- KRP $2.80
- P/E Ratio
- IOVA N/A
- KRP N/A
- Revenue Growth
- IOVA 636.99
- KRP N/A
- 52 Week Low
- IOVA $1.64
- KRP $10.98
- 52 Week High
- IOVA $12.51
- KRP $16.99
- Technical
- Relative Strength Index (RSI)
- IOVA 50.67
- KRP 35.68
- Support Level
- IOVA N/A
- KRP $13.34
- Resistance Level
- IOVA $2.46
- KRP $13.85
- Average True Range (ATR)
- IOVA 0.14
- KRP 0.26
- MACD
- IOVA -0.09
- KRP -0.04
- Stochastic Oscillator
- IOVA 92.00
- KRP 12.80
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
About KRP Kimbell Royalty Partners Common Units Representing Limited Partner Interests
Kimbell Royalty Partners LP owns and acquires mineral and royalty interests in oil and natural gas properties throughout the United States. The company's basins and producing regions include areas of interest in the Permian Basin, Mid-Continent, Terryville/Cotton Valley/Haynesville, Appalachian Basin, Eagle Ford, Bakken/Williston Basin, and DJ Basin/Rockies/Niobrara. Its revenues are derived from royalty payments received from operators based on the sale of oil, natural gas and NGL production, as well as the sale of NGLs that are extracted from natural gas during processing.